<p>根据 MarketBeat Ratings 的报告，目前有八家经纪公司对 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) 的股票给出了 “买入” 的一致推荐意见。七位研究分析师对该股票给出了买入评级，一位对该公司给出了强烈买入评级。过去一年对该股票进行评级的经纪公司的平均一年目标股价为 65.86 美元。</p>
<p>获取 <strong>Corbus Pharmaceuticals</strong> 的警报：</p>
<ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
<p>近期，几位股票研究分析师对该股票发表了看法。Oppenheimer 将 Corbus Pharmaceuticals 的股票价格目标从 80.00 美元上调至 88.00 美元，并在 8 月 7 日星期三的研究报告中给予该股票 “表现优异” 的评级。B. Riley 将 Corbus Pharmaceuticals 的股票价格目标从 85.00 美元下调至 40.00 美元，并在 9 月 20 日星期五的研究报告中给予该股票 “买入” 评级。Wedbush 将 Corbus Pharmaceuticals 的股票价格目标从 85.00 美元下调至 51.00 美元，并在 9 月 20 日星期五的研究报告中为该公司设定了 “表现优异” 的评级。Lifesci Capital 在 8 月 21 日星期三将 Corbus Pharmaceuticals 的评级提升至 “强烈买入”。最后，HC Wainwright 在 9 月 23 日星期一重申了对 Corbus Pharmaceuticals 的 “买入” 评级，并设定了 80.00 美元的目标股价。</p>
<p><strong>查看我们对 CRBP 的最新股票分析</strong></p>
<h2>Corbus Pharmaceuticals 股票下跌 3.5%</h2>
<ul>
<li>Corbus Pharmaceuticals 纳斯达克：CRBP 发出大胆买入信号</li>
</ul>
<p>周五，纳斯达克:CRBP 的股价开盘价为 19.21 美元。Corbus Pharmaceuticals 的 12 个月最低价为 3.03 美元，最高价为 61.90 美元。该公司的 50 天移动平均股价为 47.56 美元，200 天移动平均股价为 45.44 美元。该公司的市值为 2.053 亿美元，市盈率为-2.76，β系数为 2.56。</p>
<p>Corbus Pharmaceuticals (NASDAQ:CRBP) 在 8 月 6 日星期二发布了季度财报。这家生物制药公司在该季度报告中每股亏损 0.90 美元，超过了分析师预期的每股亏损 1.19 美元，超额盈利 0.29 美元。研究分析师平均预计，Corbus Pharmaceuticals 今年将实现每股-3.77 美元的盈利。</p>
<h2>内部人员的买卖行为</h2>
<p>另外，主要股东 Cormorant Asset Management, Lp 于 9 月 20 日星期五以 20.01 美元的平均价格每股购买了该公司 35 万股股票，交易总额为 700.35 万美元。交易完成后，该内部人员现持有该公司 237.5 万股股票，价值 4752.375 万美元。这笔交易导致其对该股票的持股比例增加了 0.00%。该购买行为已在提交给美国证券交易委员会的法律文件中披露，可在此链接处查看。目前公司股份的 4.00% 归公司内部人员所有。</p>
<h2>对 Corbus Pharmaceuticals 的对冲基金看法</h2>
<p>一些对冲基金最近调整了他们对 CRBP 的持股。SG Americas Securities LLC 在第三季度收购了 Corbus Pharmaceuticals 的新股份，价值 15.1 万美元。Rhumbline Advisers 在第二季度收购了 Corbus Pharmaceuticals 的新股份，价值约 63.8 万美元。Acadian Asset Management LLC 在第二季度购入了 Corbus Pharmaceuticals 的新股份，价值约 71.6 万美元。ClariVest Asset Management LLC 在第二季度收购了 Corbus Pharmaceuticals 的新股份，价值约 72.5 万美元。最后，Victory Capital Management Inc.在第二季度购入了 Corbus Pharmaceuticals 的新股份，价值约 86.2 万美元。机构投资者和对冲基金拥有该公司 64.64% 的股份。</p>
<h2>Corbus Pharmaceuticals 公司简介</h2>
<p>Corbus Pharmaceuticals Holdings, Inc 是一家生物制药公司，致力于开发产品来治疗严重疾病。该公司正在开发 CRB-701，一种抗体药物结合物（ADC），用于靶向癌细胞上的 Nectin-4 表达，释放单甲基花青素 E（MMAE）的细胞毒荷载，目前处于 I 期临床试验阶段；CRB-601，一种抗整合素单克隆抗体，用于阻断癌细胞上表达的 TGFß的激活，用于治疗实体肿瘤；CRB-913，一种外周限制性的大麻素 1（CB1）受体反向激动剂，用于治疗肥胖。</p>
<h2>精选故事</h2>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA"/></p>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ “美国即将迎来非常黑暗的一天”（来自 InvestorPlace）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njgy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njgy"/></p>
<h2>您现在是否应该投资 1000 美元购买 Corbus Pharmaceuticals 股票？</h2>
<p>在考虑投资 Corbus Pharmaceuticals 之前，您可能需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Corbus Pharmaceuticals 并不在这份名单上。</p>
<p>尽管 Corbus 制药目前在分析师中拥有&#34;买入&#34;评级，但顶级分析师认为以下这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Corbus制药控股

<p>Corbus 制药控股公司（NASDAQ:CRBP）已经获得了八家经纪公司的一致 “买入” 推荐。七位分析师给予了买入评级，而一位则给出了强烈买入评级。平均 1 年价格目标为 0.86 美元。最近的价格调整包括 Oppenheimer 将其目标价上调至 0.00 美元，而 B. Riley 将其下调至 0.00 美元。该股票今年以来上涨了 342%，当前价格为 0.21 美元。主要股东 Cormorant Asset Management 最近购买了 35 万股，将其持股量增加至 237.5 万股。机构投资者拥有公司 64.64% 的股份</p>

<p>Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of &#34;Buy&#34; from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $65.86.</p>
<div class="lb-trans"><p>根据 MarketBeat Ratings 的报告，目前有八家经纪公司对 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) 的股票给出了 “买入” 的一致推荐意见。七位研究分析师对该股票给出了买入评级，一位对该公司给出了强烈买入评级。过去一年对该股票进行评级的经纪公司的平均一年目标股价为 65.86 美元。</p>
</div><p>Get <strong>Corbus Pharmaceuticals</strong> alerts:</p>
<ul>
<li>Corbus Pharmaceuticals stock: An explosive 342% YTD surge</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Corbus Pharmaceuticals</strong> 的警报：</p>
<ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
</div><p>Several equities research analysts recently weighed in on the stock. Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $80.00 to $88.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, August 7th. B. Riley decreased their price objective on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, September 20th. Wedbush lowered their price objective on shares of Corbus Pharmaceuticals from $85.00 to $51.00 and set an &#34;outperform&#34; rating for the company in a research report on Friday, September 20th. Lifesci Capital raised Corbus Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Wednesday, August 21st. Finally, HC Wainwright reissued a &#34;buy&#34; rating and set a $80.00 price target on shares of Corbus Pharmaceuticals in a report on Monday, September 23rd.</p>
<div class="lb-trans"><p>近期，几位股票研究分析师对该股票发表了看法。Oppenheimer 将 Corbus Pharmaceuticals 的股票价格目标从 80.00 美元上调至 88.00 美元，并在 8 月 7 日星期三的研究报告中给予该股票 “表现优异” 的评级。B. Riley 将 Corbus Pharmaceuticals 的股票价格目标从 85.00 美元下调至 40.00 美元，并在 9 月 20 日星期五的研究报告中给予该股票 “买入” 评级。Wedbush 将 Corbus Pharmaceuticals 的股票价格目标从 85.00 美元下调至 51.00 美元，并在 9 月 20 日星期五的研究报告中为该公司设定了 “表现优异” 的评级。Lifesci Capital 在 8 月 21 日星期三将 Corbus Pharmaceuticals 的评级提升至 “强烈买入”。最后，HC Wainwright 在 9 月 23 日星期一重申了对 Corbus Pharmaceuticals 的 “买入” 评级，并设定了 80.00 美元的目标股价。</p>
</div><p><strong>View Our Latest Stock Analysis on CRBP</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CRBP 的最新股票分析</strong></p>
</div><h2>Corbus Pharmaceuticals Stock Down 3.5 %</h2>
<ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal</li>
</ul>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 股票下跌 3.5%</h2>
<ul>
<li>Corbus Pharmaceuticals 纳斯达克：CRBP 发出大胆买入信号</li>
</ul>
</div><p>Shares of NASDAQ:CRBP opened at $19.21 on Friday. Corbus Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $61.90. The company's 50 day moving average price is $47.56 and its two-hundred day moving average price is $45.44. The firm has a market cap of $205.30 million, a PE ratio of -2.76 and a beta of 2.56.</p>
<div class="lb-trans"><p>周五，纳斯达克:CRBP 的股价开盘价为 19.21 美元。Corbus Pharmaceuticals 的 12 个月最低价为 3.03 美元，最高价为 61.90 美元。该公司的 50 天移动平均股价为 47.56 美元，200 天移动平均股价为 45.44 美元。该公司的市值为 2.053 亿美元，市盈率为-2.76，β系数为 2.56。</p>
</div><p>Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.29. On average, research analysts expect that Corbus Pharmaceuticals will post -3.77 EPS for the current year.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals (NASDAQ:CRBP) 在 8 月 6 日星期二发布了季度财报。这家生物制药公司在该季度报告中每股亏损 0.90 美元，超过了分析师预期的每股亏损 1.19 美元，超额盈利 0.29 美元。研究分析师平均预计，Corbus Pharmaceuticals 今年将实现每股-3.77 美元的盈利。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员的买卖行为</h2>
</div><p>In other news, major shareholder Cormorant Asset Management, Lp bought 350,000 shares of the company's stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $20.01 per share, for a total transaction of $7,003,500.00. Following the completion of the transaction, the insider now owns 2,375,000 shares of the company's stock, valued at $47,523,750. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 4.00% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>另外，主要股东 Cormorant Asset Management, Lp 于 9 月 20 日星期五以 20.01 美元的平均价格每股购买了该公司 35 万股股票，交易总额为 700.35 万美元。交易完成后，该内部人员现持有该公司 237.5 万股股票，价值 4752.375 万美元。这笔交易导致其对该股票的持股比例增加了 0.00%。该购买行为已在提交给美国证券交易委员会的法律文件中披露，可在此链接处查看。目前公司股份的 4.00% 归公司内部人员所有。</p>
</div><h2>Hedge Funds Weigh In On Corbus Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Corbus Pharmaceuticals 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of CRBP. SG Americas Securities LLC acquired a new stake in Corbus Pharmaceuticals in the third quarter valued at $151,000. Rhumbline Advisers acquired a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at about $638,000. Acadian Asset Management LLC bought a new position in shares of Corbus Pharmaceuticals during the second quarter worth about $716,000. ClariVest Asset Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the second quarter worth approximately $725,000. Finally, Victory Capital Management Inc. bought a new stake in Corbus Pharmaceuticals in the second quarter valued at approximately $862,000. Institutional investors and hedge funds own 64.64% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了他们对 CRBP 的持股。SG Americas Securities LLC 在第三季度收购了 Corbus Pharmaceuticals 的新股份，价值 15.1 万美元。Rhumbline Advisers 在第二季度收购了 Corbus Pharmaceuticals 的新股份，价值约 63.8 万美元。Acadian Asset Management LLC 在第二季度购入了 Corbus Pharmaceuticals 的新股份，价值约 71.6 万美元。ClariVest Asset Management LLC 在第二季度收购了 Corbus Pharmaceuticals 的新股份，价值约 72.5 万美元。最后，Victory Capital Management Inc.在第二季度购入了 Corbus Pharmaceuticals 的新股份，价值约 86.2 万美元。机构投资者和对冲基金拥有该公司 64.64% 的股份。</p>
</div><h2>Corbus Pharmaceuticals Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 公司简介</h2>
</div><p>Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals Holdings, Inc 是一家生物制药公司，致力于开发产品来治疗严重疾病。该公司正在开发 CRB-701，一种抗体药物结合物（ADC），用于靶向癌细胞上的 Nectin-4 表达，释放单甲基花青素 E（MMAE）的细胞毒荷载，目前处于 I 期临床试验阶段；CRB-601，一种抗整合素单克隆抗体，用于阻断癌细胞上表达的 TGFß的激活，用于治疗实体肿瘤；CRB-913，一种外周限制性的大麻素 1（CB1）受体反向激动剂，用于治疗肥胖。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Corbus Pharmaceuticals</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>The Outlook for Interest Rate Cuts Got Blown Out of the Water</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore</li>
<li>What is Forex and How Does it Work?</li>
<li>3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CRBP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ “A very dark day is coming to America” (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ “美国即将迎来非常黑暗的一天”（来自 InvestorPlace）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05Njgy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9682&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Corbus Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 Corbus Pharmaceuticals 股票？</h2>
</div><p>Before you consider Corbus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Corbus Pharmaceuticals 之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Corbus Pharmaceuticals 并不在这份名单上。</p>
</div><p>While Corbus Pharmaceuticals currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Corbus 制药目前在分析师中拥有&#34;买入&#34;评级，但顶级分析师认为以下这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Corbus 制药控股公司（NASDAQ: CRBP）被券商给予 “买入” 的平均评级